Ceribell opened lower at $27.60, compared with its previous close of $27.80. In the last trading session, the stock traded between $26.29 and $27.80. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Ceribell is now worth
$ 105.40
Giving a profit of
$ 5.40 (5.40%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
$-1.45 (-5.21%)
Day High
$27.80
Day Low
$26.29
Day Open
$27.60
Prev Close
$27.80
Volume
4,02,994
1W Return
-3.66%
1M Return
4.53%
3M Return
23.60%
6M Return
31.36%
1Y Return
110.47%
Market Cap ($ Mn)
1,023
PE Ratio
-
PB Ratio
7.07
PEG Ratio
-
ROE
-30.93%
ROCE
-26.62%
EPS (TTM)
-
1 Week
-3.66%
1 Month
4.53%
3 Months
23.60%
6 Months
31.36%
9 Months
28.10%
Canaccord Genuity raises CeriBell price target to $33, maintains buy
Canaccord Genuity maintains a Buy rating on CeriBell. Price target raised from $26 to $33. Analyst William Plovanic issued the revised rating.
8 days agoCeriBell Q3FY26 Results: Revenue up 30% YoY to $29.3 million
Revenue reached $29.3 million, up 30% YoY, driven by 35 new hospital accounts and record usage per account. Net loss widened to $21.4 million from $13.5 million, largely due to increased stock-based compensation and R&D investments. Gross margin expanded to 90% from 88%, reflecting strong operational efficiency despite rising operating expenses. Full-year FY26 revenue guidance raised to $115–$117 million, excluding significant contributions from new product lines until 2027.
9 days agoCeribell sets Nov 3 date for Q3 2026 earnings release
Ceribell Inc. will release Q3 2026 financial results on November 3, 2026. Conference call scheduled for 1:30 pm PT / 4:30 pm ET on November 3. Investors can join via webcast or dial-in using access code 1880547. Company focuses on point-of-care EEG systems for acute neurological care.
23 days agoBTIG reiterates Buy on CeriBell, holds $28 price target
BTIG analyst Marie Thibault reiterates a Buy rating on CeriBell Inc. (NASDAQ: CBLL) with a maintained price target of $28. The update reflects sustained institutional confidence in the biotech firm's valuation without introducing new financial metrics or operational changes.
3mo agoCeriBell Q2 revenue rises 33%, raises FY26 guidance to $114M-$117M
CeriBell Inc. delivered strong Q2FY26 results with $28.1 million in revenue, up 33% YoY, and raised full-year guidance to $114M-$117M. Gross margin expanded to 92% aided by tariff refunds and manufacturing efficiencies, though net loss widened to $19.3 million due to commercial investments and legal costs. The company secured FDA clearances for new algorithms and hardware, plus a $60 million credit facility.
3mo agoCeribell Secures FDA 510(k) Clearance for Two AI Algorithm Enhancements
Ceribell, Inc. obtained FDA 510(k) clearance for Epileptiform Abnormality Detection and Artifact Reduction algorithms. These AI enhancements integrate into its Neurology Portal to streamline EEG interpretation by filtering interference and highlighting abnormal patterns, leveraging over one million hours of EEG data.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 3 years ago in Ceribell is now worth
$ 105.40
Giving a profit of
$ 5.40 (5.40%)
Note: Past profits do not guarantee future returns.
